Podcasts about Synthetic genomics

J. Craig Venter, PhD, ( https://www.jcvi.org/about/j-craig-venter ) is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. Dr. Venter is founder, chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 120 scientists and staff dedicated to human, microbial, synthetic, and environmental genomic research, and the exploration of social and ethical issues in genomics. Dr. Venter began his formal education after a tour of duty as a Navy Corpsman in Vietnam from 1967 to 1968. After earning both a Bachelor of Science in biochemistry and a PhD in physiology and pharmacology from the University of California at San Diego, he was appointed professor at the State University of New York at Buffalo and the Roswell Park Cancer Institute. In 1984, he moved to the National Institutes of Health campus where he developed expressed sequence tags or ESTs, a revolutionary new strategy for rapid gene discovery. In 1992, Dr. Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae, using the new whole genome shotgun technique. In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, Science. He and his team at Celera also sequenced the fruit fly, mouse, and rat genomes. Dr. Venter and his team at JCVI continue to blaze new trails in genomics. They have sequenced and analyzed hundreds of genomes, and have published numerous important papers covering such areas as environmental genomics, the first complete diploid human genome, and the groundbreaking advance in constructing the first self-replicating bacterial cell using synthetic DNA. Dr. Venter is one of the most frequently cited scientists, and the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize, and the King Faisal International Award for Science. Dr. Venter is a member of numerous prestigious scientific organizations including the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Microbiology. Dr. Venter is also a serial entrepreneur who has co-founded several companies including Synthetic Genomics, Inc., now Viridos and Human Longevity, Inc. (HLI). Dr. Venter's newest book "The Voyage of Sorcerer II: The Expedition That Unlocked the Secrets of the Ocean's Microbiome" was recently released on September 12, 2023 - https://www.amazon.com/Voyage-Sorcerer-II-Expedition-Microbiome/dp/0674246470 Support the show

Robert Downey has over 30 years of experience in upstream oil and gas and energy technology development. Prior to Shale Ingenuity, he held numerous executive and technical professional positions at Amoco, Encana, Synthetic Genomics, Ciris Energy and Gunnison Energy. He has been awarded several patents in coal bioconversion, reservoir simulation [...]

Dr. Lauren Oldfield, Director of Synthetic Genomics, Replay April 17, 2023 In this episode, we discuss efforts to develop large DNA viruses, such as herpesviruses, as vectors to deliver gene therapies, including advantages over other types of pathogen platforms. Notably, large viruses enable the delivery of larger genes for therapeutic purposes, and the characteristics of herpes simplex viruses (HSV) can allow gene therapies to be delivered over longer periods of time.

Remember all those firsts for synthetic biology that we heard about coming from Craig Venter's company, Synthetic Genomics in San Diego? The first genome of a whole organism transplanted. First genome synthesized. First synthetic life created.

We're raised to believe that right and wrong are fixed concepts. But the truth is, ethics change over time. And technology moves the goalposts on what we consider to be ethical behavior. Juan Enriquez is a leading authority on the economic impact of life sciences on business and society, and as Managing Director of Excel Venture Management, he sits on the boards of innovative healthcare startups like Openwater, WellDoc and Zipongo. Juan is the bestselling author of As the Future Catches You: How Genomics & Other Forces Are Changing Your Life, Work, Health & Wealth, and his latest release is called Right/Wrong: How Technology Transforms Our Ethics. On this episode of The Wiggin Sessions, Juan joins me to share his fears around antibiotic resistance in the aftermath of COVID-19 and discuss how the pandemic exacerbated the political and societal divisions he predicted in The Untied States of America as a long-term consequence of the financial crisis. Juan describes the synthetic genomics powering our future, explaining how factory and agricultural systems are likely to transform in what he calls the Century of Biology. Listen in for Juan's insight on reinventing the American Dream and learn how technology changes our perspective of right and wrong—and why we need to judge our ancestors and each other through a lens of context and grace. Key Takeaways Juan's fears around antibiotic resistance in the aftermath of COVID and the possible return of diseases like dengue, tuberculosis and malaria How the pandemic accelerated trends around debt, inequity, societal division and risk-taking in the financial markets How Juan predicted the political and social divisions we're experiencing now as long-term consequences of the financial crisis How technology changes our perspective of what is right and wrong (and why we need to judge our ancestors with context and grace) What happens when societies or religions don't support and adapt to innovation Juan's take on the evolution of capitalism and the need to reinvent the American Dream in a digital age The work Synthetic Genomics is doing to edit genes within bacteria to produce methane (and how it benefits the environment) The race between quantum computing and the biological storage of information How the factory system and agriculture are likely to transform in what Juan calls the Century of Biology How Excel Ventures enables entrepreneurs to solve big problems (i.e.: healthy food systems, medical imaging, diabetes management, etc.) What Juan looks for in a healthcare or life sciences company and the startups that are part of his portfolio The four factors that influence healthcare costs and why prevention vaccines are one of the most effective uses of public dollars Why it's dangerous to short-circuit the clinical trial process for vaccines for political purposes Connect with Juan Enriquez Excel Venture Management Right/Wrong: How Technology Transforms Our Ethics by Juan Enriquez Connect with Addison Wiggin Consilience Financial Be sure to follow The Wiggin Sessions on your socials. You can find me on— Facebook @thewigginsessions Instagram @thewigginsessions Twitter @WigginSessions Resources Evolving Ourselves: How Unnatural Selection and Nonrandom Mutation are Changing Life on Earth by Juan Enriquez and Steve Gullans As the Future Catches You: How Genomics & Other Forces Are Changing Your Life, Work, Health & Wealth by Juan Enriquez The Untied States of America: Polarization, Fracturing and Our Future by Juan Enriquez Synthetic Genomics Openwater WellDoc Zipongo Orionis Biosciences InfoBionic Mary Lou Jepsen's TED Talk Moderna Regeneron Pharmaceuticals Gilead Sciences INOVIO Pharmaceuticals

This research has been going on for a long time and it's all related. You can support my work at the links below. We are totally listener supported and we appreciate each and every one of you! Thank you and God bless! Express VPN Link: https://www.xvbelink.com/?offer=3monthsfree&a_fid=jstorm1 *Get 3 months Free* Select the 12 month package and get 3 months free! Bitcoin Wallet: 3M2rBQMPjS2UihwQLuzCeMTveoUSSmH87h PayPal: https://paypal.me/johnnystorm Patreon: https://patreon.com/dontspeak NEW! Cash app now available for donations! Our cash tag is $jstorm212 For checks and money orders please email us at dntspk5@gmail.com and we will send you the address. Support us through the BRAVE web browser here: https://brave.com/don308 Free book on Spiritual Warfare below! https://www.smashwords.com/books/view/780462 https://twitter.com/DontSpe54156130 Show Email dntspk5@gmail.com Back up Channel: https://www.youtube.com/channel/UCuJ9KhNAvQ49eHU7HDP6j6Q/videos Website: https://dontspeaknews.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/dontspeak/support

Ben Chiarelli is the co-founder and CEO of Cellibre. Cellibre is a cellular agriculture company that employs an organism-agnostic approach to turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. He is also the Founder, and Managing Partner of Divitempus Ventures, a venture capital and private equity firm that’s focused on investing time to create value.  Ben has held roles at Synthetic Genomics, Millennium Health, and spent nearly a decade with JP Morgan's Healthcare Investment Banking Group where he executed over $20 billion of transactions. He is the Founder and director of the 3221 Foundation, a scholarship charity founded in his brother's honor.  In this episode… It’s not easy to get funding for your business idea but imagine needing to get funding for a business idea that poses a barrier on venture capitalists to invest? Ben Chiarelli had to raise capital for a federally illegal business. He knew it would be tough because of the vice clause that makes it impossible for institution-funded venture capitals to invest in tobacco, firearms, and cannabis-related business. Ben began his search for funding in 2017 and in July 2019, he finally raised the money he needed after getting 384 NOs. So how did Ben turn the tide in his favor? Join Stephanie Sims as she speaks with Ben Chiarelli of Cellibre on this episode of What’s Your Ask where they discuss Ben’s fundraising journey, the lessons he picked up along the way, what founders can do when they get a no for an answer, and how they can get investors interested enough to look at their deck. Stay tuned. 

Eric Mathur currently serves Chief Science Officer for TILT Holdings where he oversees the Company's efforts on Cannabis molecular breeding program for the development of pure-line hybrid cultivars with defined chemical profiles tailored for specific therapeutic medical applications. His expertise and knowledge traverses' genome sciences, molecular biology, environmental microbiology, plant-microbe interactions, metagenomics, enzyme & drug discovery, plant domestication and applied biotechnology. Mathur's career spans over 35 years in basic and applied biotechnology with focus on translational science. Eric entered the San Diego biotechnology arena early, in 1983 as founder of Stratagene, where he discovered and commercialized Pfu DNA polymerase, which is still a mainstay enzyme used in the PCR industry. After a nine years' tenure, Mathur was recruited to become the first employee of Diversa Corporation, which later achieved the largest biotech IPO of the time, raising $200MM in 2001. At Diversa, Eric managed a large scientific team and multiple corporate collaborations with industrial partners including Syngenta, Dow Chemical and BASF. Following 14 years with Diversa, Mathur was recruited to start Craig Venter's company, Synthetic Genomics where he led research efforts in microbial enhanced hydrocarbon recovery sponsored by BP; he also spearheaded the genome sequencing and annotation the oil palm genome for Genting Berhad; and established a platform for plant growth promoting bacteria which led to the spinout, Agradis and subsequent Monsanto acquisition. Eric's interests then turned to plant genomics and crop domestication; he worked as Chief Science Officer for several companies including Yulex Corporation and SG Biofuels, GreenKiss NY and Cultivation.Technologies Inc., where he applied modern genomic tools and plant molecular breeding methods to accelerate plant productivity. The work culminated in dramatic yield improvements in two sustainable crops, Guayule for natural rubber production and Jatropha for biodiesel. Eric Mathur is an internationally recognized speaker who authored over 50 peer-reviewed publications and is named inventor on 100+ issued patents. Eric's passion lies in leveraging genome-based technologies to develop nutrient dense foods and therapeutic medicinals; Mathur is also an ardent supporter of sustainable agricultural and does his part to help secure global food & energy security, while minimizing the impact on our fragile environment.Find and Learn from at the following linkshttps://www.slideshare.net/slideshow/embed_code/key/8u788aek8BVDwWhttps://www.slideshare.net/slideshow/embed_code/key/zoKogkEVxdBb13To learn more about plants & your health from Colleen at LabAroma check out this informative PDF: https://mailchi.mp/2fe0e426b244/osw1lg2dkh

Today’s guest is someone I personally met on LinkedIn. He is the former Vice President of Corporate Development and Strategy at Synthetic Genomics where he was responsible for defining, evolving and implementing SGI’s strategy across all of its franchises with a focus on value creation. In that context, he was involved in managing a portfolio of internal initiatives, strategic partnerships, and transactions along with leading investor and media relations. He had a nine-year tenure on Wall Street, most recently with J.P. Morgan’s healthcare investment banking group where he advised clients on mergers and acquisitions as well as debt and equity financings. In his career on Wall Street, he executed over $20 billion in transactions. He has an MBA from Carnegie Mellon University’s Tepper School of Business and my B.S. in Mechanical Engineering from Case Western Reserve University. He is also a Founder/Director of the 32/21 Foundation, a college scholarship charity founded in his brother’s honor.

Fernanda is a business executive with over 20 years of experience in management consulting, venture investing and business operations. She spent the last 10 years working in the genomics space as Chief Business Development Officer of Human Longevity, President of SGI-DNA and Senior Vice-President at Synthetic Genomics. She recently founded Match Your Need, a local social impact technology start-up. Fernanda Coelho is a member of the San Diego French-American School board of trustees. She is also a partner at San Diego Social Venture Partners. Fernanda is originally from Brazil and moved to the United States in 2003. She is a proud mom of two daughters. Fernanda received her BS in Chemical Engineering from Escola de Engenharia Maua in Brazil and her MBA from Stanford Graduate School of Business in California. Website: matchyourneed.com Twitter: @matchyourneed

On this week's BioTech Nation, we'll hear from Dr. Herb Needleman, who measured the impact of very low levels of lead on children, and the result removed lead from household paint and put unleaded gasoline in our cars. Then, another scientist who wanted research to reach the people who needed it - Dr. Perry Nisen, CEO of Sanford Burnham Prebus Medical Discovery Institute. And Dr. Oliver Fetzer, CEO of Synthetic Genomics, enabling scientists to create unique DNA overnight in their own labs.

On this week's Tech Nation Health, we'll hear from Dr. Herb Needleman, who measured the impact of very low levels of lead on children, and the result removed lead from household paint and put unleaded gasoline in our cars. Then, another scientist who wanted research to reach the people who needed it - Dr. Perry Nisen, CEO of Sanford Burnham Prebus Medical Discovery Institute. And Dr. Oliver Fetzer, CEO of Synthetic Genomics, enabling scientists to create unique DNA overnight in their own labs.

J. Craig Venter, founder, chair and CEO of the J. Craig Venter Institute and co-founder of two private genomics companies, recounts his breakthroughs in genome sequencing and shares new research on fighting cancer tumors with personalized vaccines. Venter is presented by the Altman Clinical and Translational Research Institute at UC San Diego. Series: "Wellbeing " [Health and Medicine] [Professional Medical Education] [Show ID: 31734]

J. Craig Venter, founder, chair and CEO of the J. Craig Venter Institute and co-founder of two private genomics companies, recounts his breakthroughs in genome sequencing and shares new research on fighting cancer tumors with personalized vaccines. Venter is presented by the Altman Clinical and Translational Research Institute at UC San Diego. Series: "Wellbeing " [Health and Medicine] [Professional Medical Education] [Show ID: 31734]

J. Craig Venter, founder, chair and CEO of the J. Craig Venter Institute and co-founder of two private genomics companies, recounts his breakthroughs in genome sequencing and shares new research on fighting cancer tumors with personalized vaccines. Venter is presented by the Altman Clinical and Translational Research Institute at UC San Diego. Series: "Wellbeing " [Health and Medicine] [Professional Medical Education] [Show ID: 31734]

J. Craig Venter, founder, chair and CEO of the J. Craig Venter Institute and co-founder of two private genomics companies, recounts his breakthroughs in genome sequencing and shares new research on fighting cancer tumors with personalized vaccines. Venter is presented by the Altman Clinical and Translational Research Institute at UC San Diego. Series: "Wellbeing " [Health and Medicine] [Professional Medical Education] [Show ID: 31734]

Bryan Johnson is an entrepreneur and investor. He is the founder of OS Fund and Braintree, the latter of which was bought by eBay in 2013 for $800 million in cash. Bryan launched OS Fund in 2014 with $100 million of his personal capital to support inventors and scientists who aim to benefit humanity by rewriting the operating systems of life. He cultivates real-world mad scientists. Our conversation includes his rags to riches story (and strategies), his philosophical hardwiring, negotiating/sales tactics, and even parenting. We cover a ton of ground with a fascinating and deep mind. Bryan's investments include endeavors to cure age-related diseases and radically extend healthy human life to 100+ (Human Longevity), make biology a predictable programming language (Gingko Bioworks & Synthetic Genomics), replicate the human visual cortex using artificial intelligence (Vicarious), mine an asteroid (Planetary Resources), reinvent transportation using autonomous vehicles (Mattternet), and reimagine food using biology (Hampton Creek), among others. Enjoy! Please check out the sponsors for this episode, which I’ve used myself: Athletic Greens —My all-in-one nutritional insurance policy. 99Designs — Your one-stop shop for all things graphic design related. I used them for the book cover mockups for The 4-Hour Body, which later hit #1 New York Times. Show notes (links, resources, books, etc.) from this episode can be found on my blog here: http://fourhourworkweek.com/podcast.***If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it really makes a difference in helping to convince hard-to-get guests. I also love reading the reviews!For show notes and past guests, please visit tim.blog/podcast.Sign up for Tim’s email newsletter (“5-Bullet Friday”) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Interested in sponsoring the podcast? Visit tim.blog/sponsor and fill out the form.Discover Tim’s books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissFacebook: facebook.com/timferriss YouTube: youtube.com/timferriss

Here's my summary of the fourth and final day of ASM2013, with a special surprise guest appearance at the end! Download Episode (5.5 MB, 6 minutes) Session 1: Synthetic Genomics to Create a Minimal Bacterial Cell and Some Other Neat Stuff Presented by John I. Glass He talked about the cell with the synthetic genome (full episode 13), and about how important it is to determine what is the minimal amount of genome a cell needs to grow--knowing that, you can start there and build almost anything you want. He also talked about a new method of producing new flu strains for vaccine production using synthetic nucleic acids, which could greatly shorten the time it takes to get a new vaccine going to counter a pandemic. Session 2: C. difficile vs. the Microbiota: The Enemy of My Enemy is My Friend Presented by Shonna McBride When a probiotic (Lactococcus lactis) was grown with C. difficile, the latter was killed. Session 3: An Intriguing Bacterial Symbiont in the Nucleus of Amoebae Presented by Frederik SchulzInteractions between amoebae and bacteria are interesting and also relevant to our health, considering the similarities between amoebae and cells of our immune system. This interaction is particularly interesting: bacteria living inside the nucleus. Post questions or comments here or email to bacteriofiles at gmail dot com. Thanks for listening! Subscribe at iTunes, check out the show at Twitter or Facebook

BIO5